Cytokinetics Inc vs Ishares Msci Brazil ETF — how do they compare? Cytokinetics Inc trades at $75.57 (market cap $10.63B), while Ishares Msci Brazil ETF trades at $33.84. The key difference: Cytokinetics Inc is trading nearer its 52-week high, Ishares Msci Brazil ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | EWZ | |
|---|---|---|
Market Cap | $10.63B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $87.26 | $41.75 |
52-Week Low | $34.31 | $27.36 |
Enterprise Value | $10.74B | — |
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $76.24, down 1.61% over 24 hours, with a bearish technical signal from moving averages and neutral oscillators. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, while revenue reached $88.04 million in 2025. Despite negative profitability margins, strong analyst sentiment exists with 34 buy ratings and a consensus price target of $111.14, driven by optimism around Myqorzo's commercial uptake and recent UK regulatory approval.
The outlook hinges on Myqorzo's commercial execution and pipeline expansion, offering significant upside if revenue growth accelerates. Key risks include persistent cash burn, high debt-to-asset ratio of 81.23%, and competitive pressures in the cardiovascular drug market. Investors should weigh the high valuation (P/S of 140.65) against the potential for future profitability breakthroughs.
EWZ, the iShares MSCI Brazil ETF, trades at $34.04, down 3.27% on the day. The technical outlook is bearish based on moving averages, though oscillators suggest potential for a near-term bounce. Recent news highlights institutional interest, with Empowered Funds LLC and Allspring Global Investments increasing positions in Q2 2026, while analysts debate the fund's value relative to competitors like FLBR due to its higher expense ratio.
The outlook for EWZ hinges on Brazil's economic trajectory, particularly interest rate cuts and commodity prices. Opportunities exist if Brazil's growth accelerates, but risks include U.S. tariff impacts on Brazilian exports and inconsistent dividend payouts reliant on volatile commodity stocks like Petrobras and Vale.
Trailing returns across standard periods
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →